Long-COVID Post-COVID Characterization of abberant immune response in post-COVID using innovative signal transduction pathway technology (LC-STP)
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Long-COVID patients • Age >= 18 years, 6 months Healthy controls • Age >= 18 years, 95% compared to functioning prior COVID-19 infection • Self-reported general good wellbeing • Provided written informed consent
Exclusion criteria
Exclusion criteria: Long-COVID patients • Unable or not willing to provide written informed consent • Unable to complete written questionnaires in Dutch • Unable to draw blood for study purposes • Diagnosis of dementia • Alternative diagnosis that may explain their clinical symptoms • Re-infection or booster vaccination with COVID-19 in the past 3 months • Suffering from any pre-existing immune-driven disease or use of anti-inflammatory therapy of any kind (including NSAIDs and steroids) during the last 3 months Healthy controls • Unable or not willing to provide written informed consent • Unable to complete written questionnaires in Dutch • Unable to draw blood for study purposes • Diagnosis of dementia • Genetically related to participating patients (e.g. brother/sister/parent) • Suffering from any immune-driven disease or use of anti-inflammatory therapy of any kind (including NSAIDs and steroids), including during the last 3 months • Re-infection with SARS-CoV-2 or booster vaccination in the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transcriptome analysis by STP technology delivers a an STP activity score for 15 STPs, for each analyzed immune cell type sample (CD4+ T-, CD8+ T-, B-lymphocytes, NK cells, monocytes). The main study parameters are the STP activity score of 15 STP pathways of the 5 types of immune cells. The main goal is to compare STP activity between long-COVID and controls. | — |
Secondary
| Measure | Time frame |
|---|---|
| We will biologically interpretate the abnormal immune function/ STP activity profile in individual long-COVID patients followed by identification and description of potential STP drug targets by DCDC-Tx. If applicable, we will assess for long-COVID subtypes, based on interpretation of STP results (regarding differential immune cell dysfunction and treatment targets) in combination with clinical and/or other laboratory parameters. Several biomarkers implicated in long-COVID and related to immune dysregulation will be measured in serum (including but not limited to) cortisol, cytokines (primarily CCL2, CCL11, galectin-1, galectin-9, IL-6, IL-8, IL-10, CXCL10 and sCD163 (a macrophage activation marker). | — |
Countries
Netherlands
Contacts
Public ContactW.A. Dik
Erasmus MC, Universitair Medisch Centrum Rotterdam
Outcome results
None listed